Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are being investigated for potential health benefits beyond diabetes treatment. A study is examining whether Novo's Wegovy can reduce alcohol intake in patients with early Alzheimer's disease. Another study is testing Novo's semaglutide in combination with clot removal therapy for stroke patients. Lilly is also conducting research on the effects of their drugs on Alzheimer's disease and obesity.
Eli Lilly 's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound , as well as Novo Nordisk 's rival medicines Ozempic and Wegovy , are being studied to see whether they can improve health in other ways. Novo's Wegovy for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
A study by the University of Copenhagen's Psychiatric Centre Rigshospitalet is investigating whether semaglutide, sold as Novo's Wegovy and Ozempic, can help reduce alcohol intake in testing semaglutide in patients with early Alzheimer's disease. The study, which will enrol 1,840 patients, could reach primary completion as early as 2025. and obesity. Lilly plans to enrol about 700 people in the study, which is expected to be completed by July 2024. Researchers at the Chinese University of Hong Kong are testing Novo's semaglutide along with the mechanical removal of clots in patients with strokes caused by the blockage of large blood vessels to the brain. The approach will be compared with standard therap
Eli Lilly Novo Nordisk Diabetes Drug Mounjaro Weight-Loss Therapy Zepbound Ozempic Wegovy Health Benefits Alcohol Intake Alzheimer's Disease Stroke Clot Removal Therapy Research Obesity